Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.10.03 | Calcium, Vitamin D and Bone | ECE2015

Local administration of non-diabetic MSCs to diabetic femoral fractures enhances callus remodelling and deposition of reparative bone

Watson Luke , Chen Xi Zhe , Ryan Aideen , Loftus Paul , McDonnell Patrick , O'Brien Timothy , Coleman Cynthia

Fractures in diabetic patients are slower to heal and have an increased risk for developing malunion as compared to non-diabetic individuals. Given the known deficiencies in diabetic progenitor cell number and differentiation capacity, it is reasonable to hypothesise the aetiology of diabetic fracture malunion is dysregulated progenitor function. Therefore, we investigated the therapeutic efficacy of locally administered non-diabetic human bone marrow derived mesenchymal stem ...

ea0037gp.15.01 | Diabetes and obesity – basic | ECE2015

Topical application of CD362+ human mesenchymal stem cells (cyndacel-M) seeded in Excellagen scaffold augments wound healing and increases angiogenesis in a diabetic rabbit ulcer model

Patil Swapnil , Chen Xizhe , Watson Luke , Loftus Paul , Flynn Lisa O' , Chandler Lois , Rubanyi Gabor , Elliman Stephen , O'Brien Timothy

Non-healing foot ulcers are a major complication in diabetic patients. Mesenchymal stem cells (MSCs) are known to promote angiogenesis with improved wound healing. Orbsen Therapeutics has identified a novel antibody (CD362+) which can be used to prospectively FACS-isolate CD362+CD45− MSC from human bone marrow with enhanced MSC/MNC purity ratios of up to 1/4. Excellagen matrix was used to seed the cells as biomaterials are well reported t...